Vermillion Completes Acquisition of Correlogic Ovarian Cancer Dx Business | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion today said that it has completed the acquisition of the assets associated with Correlogic Systems' ovarian cancer diagnostics business for $435,000 in cash.

Vermillion said early last month that it had acquired the assets of Correlogic, a firm operating under Chapter 11 bankruptcy protection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.